144 related articles for article (PubMed ID: 30143452)
1. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
[TBL] [Abstract][Full Text] [Related]
2. Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis.
Liu M; Cui LH; Li CC; Zhang L
Eur J Cancer Prev; 2015 Nov; 24(6):470-83. PubMed ID: 25853848
[TBL] [Abstract][Full Text] [Related]
3. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
[TBL] [Abstract][Full Text] [Related]
4. p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA).
Lv X; Ye G; Zhang X; Huang T
Medicine (Baltimore); 2017 Sep; 96(38):e8106. PubMed ID: 28930859
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma.
Csepregi A; Ebert MP; Röcken C; Schneider-Stock R; Hoffmann J; Schulz HU; Roessner A; Malfertheiner P
BMC Cancer; 2010 Jun; 10():317. PubMed ID: 20569442
[TBL] [Abstract][Full Text] [Related]
6. Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analysis.
Li CC; Yu Z; Cui LH; Piao JM; Liu M
Asian Pac J Cancer Prev; 2014; 15(16):6591-6. PubMed ID: 25169493
[TBL] [Abstract][Full Text] [Related]
7. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis.
Qin Y; Liu JY; Li B; Sun ZL; Sun ZF
World J Gastroenterol; 2004 May; 10(9):1276-80. PubMed ID: 15112341
[TBL] [Abstract][Full Text] [Related]
8. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
[TBL] [Abstract][Full Text] [Related]
9. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.
Wu HC; Yang HI; Wang Q; Chen CJ; Santella RM
Carcinogenesis; 2017 Oct; 38(10):1021-1028. PubMed ID: 28981677
[TBL] [Abstract][Full Text] [Related]
10. Correlation between promoter methylation in the GSTP1 gene and hepatocellular carcinoma development: a meta-analysis.
Li QF; Li QY; Gao AR; Shi QF
Genet Mol Res; 2015 Jun; 14(2):6762-72. PubMed ID: 26125884
[TBL] [Abstract][Full Text] [Related]
11. Association of GSTP1 and P16 promoter methylation with the risk of HBV-related hepatocellular carcinoma: a meta-analysis.
Li Q; Deng C; Zhang T; Li X
Onco Targets Ther; 2018; 11():5789-5796. PubMed ID: 30254471
[TBL] [Abstract][Full Text] [Related]
12. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma.
Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G
Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
Cao Z; Wei L; Zhu W; Yao X
Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic effects of
Xia L; Zhang W; Gao L
Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
[No Abstract] [Full Text] [Related]
15. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
[TBL] [Abstract][Full Text] [Related]
16. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
[TBL] [Abstract][Full Text] [Related]
17. Aberrant promoter methylation of SOCS-1 gene may contribute to the pathogenesis of hepatocellular carcinoma: a meta-analysis.
Zhao RC; Zhou J; He JY; Wei YG; Qin Y; Li B
J BUON; 2016; 21(1):142-51. PubMed ID: 27061542
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A methylation in esophageal cancer: a meta-analysis.
Zhou C; Li J; Li Q
Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
[TBL] [Abstract][Full Text] [Related]
19. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
[TBL] [Abstract][Full Text] [Related]
20. Interferon-γ +874A/T polymorphism and hepatocellular carcinoma risk: a meta-analysis.
Zhou H; Wang L; Li X; Song J; Jiang T; Wu X; Zhou S
Med Sci Monit; 2015 Mar; 21():689-93. PubMed ID: 25739411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
